New study tracks MS patients on ozanimod: will they stick with it?
NCT ID NCT05811416
First seen Jan 07, 2026 · Last updated May 09, 2026 · Updated 23 times
Summary
This study follows about 200 people with relapsing-remitting multiple sclerosis (RRMS) who are starting the drug ozanimod for the first time. Researchers want to see how long patients continue taking the medication and how well it controls their MS over two years. The goal is to understand real-world use of ozanimod in patients with mild to moderate disease activity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Local Institution - 0001
Barcelona, 08008, Spain
Conditions
Explore the condition pages connected to this study.